Syntometrine: Labour & birth suite-Quick reference guide

This document should be read in conjunction with this Disclaimer

Note: This Quick Reference Guide must be used in conjunction with its respective Clinical Guideline: Obstetrics & Gynaecology, Labour: Third Stage: Active Management

Syntometrine - Labour & birth suite

Indications:

- Active management of the third stage of labour for women at high risk of PPH
- Prevention or treatment of PPH

Contraindications- DO NOT give when:

- Hypertension / pre-eclampsia/ eclampsia
- Cardiac disease (moderate/severe) or severe peripheral vascular disease; severe hepatic or renal impairment; sepsis
- Unknown history (antenatal or medical) & imminent birth, including precipitous birth where blood pressure not checked
- Fibroids (severe); or allergy to oxytocin / ergometrine

Precautions- avoid with:

- Ischaemic heart disease; peripheral vascular disease; hypertension; migraine; Raynaud’s phenomenon; respiratory disease; chronic anaemia; or pregnancy
- Breech presentations- administer only after birth completed
- Multiple births (including possible undiagnosed multiple birth e.g. no pregnancy ultrasound)- give only after all fetuses have birthed

Note: This QRG represents minimum care & should be read in conjunction with the following information, Syntometrine, PPH & Third Stage (Active Management) guidelines & relevant guidelines as required. Care should be individualised.

Key points

1. For active management of the third stage of labour, intramuscular oxytocin (not Syntometrine) should be the routine drug given.4

2. Syntometrine® intramuscular injection is used for active management of the third stage of labour in women identified as high risk for postpartum
haemorrhage (PPH) who do not have any contraindications to its use.

3. For postpartum haemorrhage management where oxytocin is not available or the bleeding does not respond to oxytocin, Syntometrine is recommended\(^6\) (if not already given for prophylaxis or contraindicated).

4. For PPH risks, prevention and management, see KEMH Clinical Guideline, Restricted Area Guidelines (Intranet only) Primary Postpartum Haemorrhage.

5. No more than 2 doses of ergometrine should be given due to the side-effects.\(^7\)

**Background**

Syntometrine\(^\circledR\) contains oxytocin 5 units & ergometrine 0.5mg.\(^7, 8\) The oxytocin within intra-muscular Syntometrine acts rapidly (within 2 ½ minutes) and is short acting, whilst the ergometrine acts within 6-7 minutes and lasts 2-4 hours.\(^7\) Associated side effects of ergometrine based medications include elevated blood pressure, nausea, vomiting,\(^7, 10, 11\) vasoconstriction, dizziness, abdominal pain, headache and seizures.\(^13, 14\) In hypertensive women, syntometrine can worsen hypertension and is contraindicated.\(^4\)

A UK report\(^4, 5\) on maternal mortality recommends that the routine use of syntometrine be avoided completely (p.69), with preference given to using intramuscular oxytocin (without ergometrine).

**Indications for use\(^8, 16\)**

1. Active management of the third stage of labour
2. Prevention or treatment of PPH. See Risk Factors for PPH section on next page.

**Contraindications to the use of syntometrine\(^\circledR\)**

- Pre-eclampsia\(^5, 16\) or eclampsia,\(^5, 14\) hypertensive disorders\(^14\)
- Moderate-to-severe cardiac disease or severe peripheral vascular disease\(^16\)
- No knowledge of the woman’s antenatal and medical history and the birth is imminent, including women with precipitous labours in whom blood pressure has not been checked.\(^4\)
- Severe hepatic impairment\(^16\), renal failure or sepsis\(^8\). Avoid use as sensitivity to ergometrine is increased\(^14\)
- Severe fibroids\(^16\); allergy to oxytocin\(^5, 18\) or ergometrine\(^8\)

NB: Although pre-eclampsia,\(^2, 12\) hypertensive disease in pregnancy\(^1, 3, 5\), severe fibroids\(^16\) and sepsis are identified risk factors for postpartum haemorrhage, women with these conditions must not be given Syntometrine.

**Precautions**

- Pre-existing pulmonary, cardiac or vascular disorders: Ischaemic heart disease, peripheral vascular disease or hypertension may be exacerbated\(^15\);
migraine; Raynaud’s phenomenon (extreme vasoconstriction of peripheral blood vessels)\(^7,13\); respiratory disease or chronic anaemia

- Pregnancy\(^8\)- Category C; Not indicated\(^{15}\)
- Breech presentations – ensure administration occurs after the birth is completed\(^8\)
- Multiple births- ensure that administration only occurs after the birth of the last fetus\(^8\) (e.g. second twin) otherwise excessive uterine contraction can result in death of the subsequent fetus(es).\(^{15}\) If possibility of an undiagnosed second twin (e.g. no ultrasound in pregnancy), exercise caution before administering oxytocic.\(^{10}\).

### Risk factors for PPH

An increased risk of PPH is associated with:

- **Demographics**: Age (>35)\(^1\); Ethnicity (hispanic\(^2\), asian); Obesity (BMI > 35)
- **Medical history**: Anaemia\(^3\) (<90g/L)\(^5\); Medical disorders (e.g. Von Willebrand’s/coagulopathies\(^9\), or diabetes\(^1\)); Anticoagulant therapy\(^9,10\)
- **Previous obstetric history**: Past history of PPH\(^{12}\), retained placenta or MROP\(^3\); previous caesarean birth\(^1,3\)
- **Antenatal history**: Antepartum haemorrhage\(^3\); Chorioamnionitis\(^1-3,12\); Over-distended uterus (polyhydramnios, multiple gestation\(^\ast,15\), macrosomia\(^1-3,5,12\); Grand multiparity\(^1,3,15\); parity 5 or more; Primigravidity\(^9\); Placental abnormalities e.g. Placenta prævia, or suspected / proven abruptio placenta\(^1,3,5\); Tocolytic drugs\(^3\) (e.g. Antepartum use of magnesium sulphate\(^2\), nifedipine, salbutamol); Fetal demise\(^17\)
- **Labour**: Induction of labour\(^1\) or augmentation\(^2,3,12\); Oxytocin exposure in labour (prolonged use or higher maximal dose)\(^2\); Malpresentation\(^\ast\) (other than cephalic)\(^1\); Prolonged labour\(^3,12\) (e.g. First stage ≥ 12hrs, Second stage ≥ 3hrs) or third stage\(^2\); Pyrexia in labour\(^5\); Rapid or in-coordinate labour\(^{12}\)
- **Birth**: Caesarean section\(^1,12\) or operative/instrumental vaginal birth\(^1,2,5,12\); Episiotomy\(^2\)- mediolateral\(^5\); General anaesthetic\(^2,3\); Retained placenta\(^3\) or products\(^2\); Uterine inversion\(^3\), uterine rupture or cervical laceration\(^1\); Mismanaged third stage (massaging uterus causing partial separation of placenta)\(^3\)

**Note**: PPH may occur when there are no risk factors identified.\(^{12,15}\)

\(^\ast\) See [Precautions](#) on previous page.

See also Restricted Area Guideline (Intranet only): Postpartum Haemorrhage
References


Related legislation and policies (list and hyperlink)

**Legislation:** *Poisons Act 1964*

**Policy:** Department of Health WA: OD 0657/16 *WA Health Consent to Treatment Policy 2016*

Related WNHS policies, procedures and guidelines

KEMH Clinical Guidelines:
- Obstetrics & Gynaecology: Labour & Birth: Second Stage; Labour: *Third Stage; Retained Placenta*; Medications During Labour & Birth: *Guidelines for Prescribing*;
- Pharmacy: *Syntometrine*; Medication Safety: Administration of Medications
- *Restricted Area Guidelines* *(Intranet only)*: Primary Postpartum Haemorrhage (PPH)

Useful resources (including related forms)

**Form:** MR810.04 Medication Administered for Labour & Birth

<table>
<thead>
<tr>
<th>Keywords:</th>
<th>syntometrine, oxytocic, ergometrine, third stage, postpartum haemorrhage prevention, active management of third stage, labour suite, LBS, QRG, uterotonic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document owner:</td>
<td>OGID</td>
</tr>
<tr>
<td>Author / Reviewer:</td>
<td>Head of Department Obstetrics</td>
</tr>
<tr>
<td>Date first issued:</td>
<td>Nov 2003</td>
</tr>
<tr>
<td>Reviewed dates:</td>
<td>; Sept 2015; Oct 2018</td>
</tr>
<tr>
<td>Supersedes:</td>
<td>Version dated Sept 2015</td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>MSMSC</td>
</tr>
<tr>
<td>NSQHS Standards (v2) applicable:</td>
<td>1 Governance, 4 Medication Safety</td>
</tr>
</tbody>
</table>

Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.